JP2013537203A - 三環式化合物、製造方法、およびそれらの使用 - Google Patents
三環式化合物、製造方法、およびそれらの使用 Download PDFInfo
- Publication number
- JP2013537203A JP2013537203A JP2013528497A JP2013528497A JP2013537203A JP 2013537203 A JP2013537203 A JP 2013537203A JP 2013528497 A JP2013528497 A JP 2013528497A JP 2013528497 A JP2013528497 A JP 2013528497A JP 2013537203 A JP2013537203 A JP 2013537203A
- Authority
- JP
- Japan
- Prior art keywords
- trifluoromethyl
- oxy
- chloro
- phenyl
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 COc(cc1)cc(CCN23)c1C2=CC(*CCc(cc1)cc(C#N)c1Oc1ncc(C(F)(F)F)cc1)=NC3=O Chemical compound COc(cc1)cc(CCN23)c1C2=CC(*CCc(cc1)cc(C#N)c1Oc1ncc(C(F)(F)F)cc1)=NC3=O 0.000 description 2
- PGTLFIGYEWNNOH-UHFFFAOYSA-N COc(cc1)cc(CCN23)c1C2=CC(OCc(ccc(Oc(cc1)cc(C(F)(F)F)c1Cl)c1)c1C#N)=NC3=O Chemical compound COc(cc1)cc(CCN23)c1C2=CC(OCc(ccc(Oc(cc1)cc(C(F)(F)F)c1Cl)c1)c1C#N)=NC3=O PGTLFIGYEWNNOH-UHFFFAOYSA-N 0.000 description 2
- FFIANHVBVFPUHD-UHFFFAOYSA-N Brc1ccccc1CCOC1OCCCC1 Chemical compound Brc1ccccc1CCOC1OCCCC1 FFIANHVBVFPUHD-UHFFFAOYSA-N 0.000 description 1
- LNPBODQZZISPCB-ULERAKTPSA-N C/C(/C#N)=C\C(\Oc(ccc(C=O)c1)c1Cl)=C/N=C Chemical compound C/C(/C#N)=C\C(\Oc(ccc(C=O)c1)c1Cl)=C/N=C LNPBODQZZISPCB-ULERAKTPSA-N 0.000 description 1
- ZODHPLMTOYEEOM-IOJGMCHMSA-N C/C=C\C=C(/N=[I]/C(F)(F)F)\OC1=CCCC=C1C#N Chemical compound C/C=C\C=C(/N=[I]/C(F)(F)F)\OC1=CCCC=C1C#N ZODHPLMTOYEEOM-IOJGMCHMSA-N 0.000 description 1
- KZIXVFDDFIEDPM-UHFFFAOYSA-N C=Cc(cc1)cc(C#N)c1Oc1cc(C(F)(F)F)ccc1 Chemical compound C=Cc(cc1)cc(C#N)c1Oc1cc(C(F)(F)F)ccc1 KZIXVFDDFIEDPM-UHFFFAOYSA-N 0.000 description 1
- RPJYEVANEOGLFM-UHFFFAOYSA-N C=Cc(cc1)cc(C#N)c1Oc1cccc(C(F)(F)F)n1 Chemical compound C=Cc(cc1)cc(C#N)c1Oc1cccc(C(F)(F)F)n1 RPJYEVANEOGLFM-UHFFFAOYSA-N 0.000 description 1
- IHSJAHYEAPHXJI-UHFFFAOYSA-N C=Cc(cc1)cc(C#N)c1Oc1ncc(C(F)(F)F)cc1 Chemical compound C=Cc(cc1)cc(C#N)c1Oc1ncc(C(F)(F)F)cc1 IHSJAHYEAPHXJI-UHFFFAOYSA-N 0.000 description 1
- FLBJVSACTWSENJ-UHFFFAOYSA-N C=Cc(cc1)ncc1Oc1cccc(C(F)(F)F)c1 Chemical compound C=Cc(cc1)ncc1Oc1cccc(C(F)(F)F)c1 FLBJVSACTWSENJ-UHFFFAOYSA-N 0.000 description 1
- FDZKIRPIFSBZJH-UHFFFAOYSA-N CC(C=C1)=NCC1Oc1ccc(C=O)cc1Cl Chemical compound CC(C=C1)=NCC1Oc1ccc(C=O)cc1Cl FDZKIRPIFSBZJH-UHFFFAOYSA-N 0.000 description 1
- XQEFYTAGPCEVRM-UHFFFAOYSA-N CC1(C)OB(c(cc2C#N)ccc2Oc2cccc(C(F)(F)F)c2)OC1(C)C Chemical compound CC1(C)OB(c(cc2C#N)ccc2Oc2cccc(C(F)(F)F)c2)OC1(C)C XQEFYTAGPCEVRM-UHFFFAOYSA-N 0.000 description 1
- DDGWOYWIMKTSFK-UHFFFAOYSA-N CNCc(cc1C#N)ccc1Oc1cc(C#N)cnc1 Chemical compound CNCc(cc1C#N)ccc1Oc1cc(C#N)cnc1 DDGWOYWIMKTSFK-UHFFFAOYSA-N 0.000 description 1
- OHNWJFZRTMTWNI-UHFFFAOYSA-N COC1C=CC(C(N2CC3)=CC(OCCc(cc4)cc(F)c4Oc4cccc(C(F)(F)F)n4)=NC2=O)=C3C1 Chemical compound COC1C=CC(C(N2CC3)=CC(OCCc(cc4)cc(F)c4Oc4cccc(C(F)(F)F)n4)=NC2=O)=C3C1 OHNWJFZRTMTWNI-UHFFFAOYSA-N 0.000 description 1
- NIBGNGBQRGQUCF-ZUWFHJRGSA-N COCC/C=C(/C(N1)=CC(OCC2N=CC(Oc(cc3)cc(C(F)(F)F)c3F)=CC2)=N[I]1O)\I Chemical compound COCC/C=C(/C(N1)=CC(OCC2N=CC(Oc(cc3)cc(C(F)(F)F)c3F)=CC2)=N[I]1O)\I NIBGNGBQRGQUCF-ZUWFHJRGSA-N 0.000 description 1
- HIVZOSXHEVHIKK-UHFFFAOYSA-N COc(cc1)cc(CCN23)c1C2=CC(OCCc(cc1)cc(C#N)c1Oc1ccc(C(F)(F)F)nc1)=NC3=O Chemical compound COc(cc1)cc(CCN23)c1C2=CC(OCCc(cc1)cc(C#N)c1Oc1ccc(C(F)(F)F)nc1)=NC3=O HIVZOSXHEVHIKK-UHFFFAOYSA-N 0.000 description 1
- APALWHCPXDAQOM-UHFFFAOYSA-N COc(cc1)cc(CCN23)c1C2=CC(OCCc(nc1)ccc1Oc1cc(C(F)(F)F)ccc1)=NC3=O Chemical compound COc(cc1)cc(CCN23)c1C2=CC(OCCc(nc1)ccc1Oc1cc(C(F)(F)F)ccc1)=NC3=O APALWHCPXDAQOM-UHFFFAOYSA-N 0.000 description 1
- XVDLAHZHSOIOHS-UHFFFAOYSA-N COc(cc1)cc(CCN23)c1C2=CC(OCc(cc1)cc(F)c1Oc1cnc(C(F)(F)F)nc1)=NC3=O Chemical compound COc(cc1)cc(CCN23)c1C2=CC(OCc(cc1)cc(F)c1Oc1cnc(C(F)(F)F)nc1)=NC3=O XVDLAHZHSOIOHS-UHFFFAOYSA-N 0.000 description 1
- CAJNHXNTJCPXQL-UHFFFAOYSA-N COc(cc1)cc(CCN23)c1C2=CC(OCc(cc1F)cnc1Oc(cc1)cc(C(F)(F)F)c1Cl)=NC3=O Chemical compound COc(cc1)cc(CCN23)c1C2=CC(OCc(cc1F)cnc1Oc(cc1)cc(C(F)(F)F)c1Cl)=NC3=O CAJNHXNTJCPXQL-UHFFFAOYSA-N 0.000 description 1
- YYTRTXWJGWACAY-UHFFFAOYSA-N COc(cc1)cc(CCN23)c1C2=CC(OCc(ccc(Oc1cc(C(F)(F)F)ccc1)c1)c1C#N)=NC3=O Chemical compound COc(cc1)cc(CCN23)c1C2=CC(OCc(ccc(Oc1cc(C(F)(F)F)ccc1)c1)c1C#N)=NC3=O YYTRTXWJGWACAY-UHFFFAOYSA-N 0.000 description 1
- GYBHYFYZRHZIDA-UHFFFAOYSA-N COc(cc1)cc(CCN23)c1C2=CC(OCc(cn1)ccc1Oc1cc(C(F)(F)F)ccc1)=NC3=O Chemical compound COc(cc1)cc(CCN23)c1C2=CC(OCc(cn1)ccc1Oc1cc(C(F)(F)F)ccc1)=NC3=O GYBHYFYZRHZIDA-UHFFFAOYSA-N 0.000 description 1
- RVWYQSNFCNBIBK-UHFFFAOYSA-N COc(cc1CCN23)ccc1C2=CC(OCc(cc1)cc(C#N)c1Oc1cnc(C(F)(F)F)nc1)=NC3=O Chemical compound COc(cc1CCN23)ccc1C2=CC(OCc(cc1)cc(C#N)c1Oc1cnc(C(F)(F)F)nc1)=NC3=O RVWYQSNFCNBIBK-UHFFFAOYSA-N 0.000 description 1
- WBIVBAPHPMEJJY-UHFFFAOYSA-N COc(cc1CCN23)ccc1C2=CC(OCc(ccc(Oc1ccc(C(F)(F)F)nc1)c1)c1Cl)=NC3=O Chemical compound COc(cc1CCN23)ccc1C2=CC(OCc(ccc(Oc1ccc(C(F)(F)F)nc1)c1)c1Cl)=NC3=O WBIVBAPHPMEJJY-UHFFFAOYSA-N 0.000 description 1
- GFMSEJBKNAOORZ-UHFFFAOYSA-N Cc(cc1)cc(CCN23)c1C2=CC(OCc(cc1)cc(C#N)c1Oc(cc1)cc(C(F)(F)F)c1Cl)=NC3=O Chemical compound Cc(cc1)cc(CCN23)c1C2=CC(OCc(cc1)cc(C#N)c1Oc(cc1)cc(C(F)(F)F)c1Cl)=NC3=O GFMSEJBKNAOORZ-UHFFFAOYSA-N 0.000 description 1
- OWZUUYCRFZYKLM-UHFFFAOYSA-N Cc(cc1)cc(CCN23)c1C2=CC(OCc(cc1)cc(C#N)c1Oc1cccc(C(F)(F)F)n1)=NC3=O Chemical compound Cc(cc1)cc(CCN23)c1C2=CC(OCc(cc1)cc(C#N)c1Oc1cccc(C(F)(F)F)n1)=NC3=O OWZUUYCRFZYKLM-UHFFFAOYSA-N 0.000 description 1
- GJFYGPSPJUZYBL-UHFFFAOYSA-N Cc(cc1)cc(CCN23)c1C2=CC(OCc(cc1)cc(F)c1Oc1ccc(C(F)(F)F)cn1)=NC3=O Chemical compound Cc(cc1)cc(CCN23)c1C2=CC(OCc(cc1)cc(F)c1Oc1ccc(C(F)(F)F)cn1)=NC3=O GJFYGPSPJUZYBL-UHFFFAOYSA-N 0.000 description 1
- LQZQSZYECYSUFV-UHFFFAOYSA-N Cc(cc1)cc(CCN23)c1C2=CC(OCc(cc1F)cc(F)c1Oc1cnc(C(F)(F)F)nc1)=NC3=O Chemical compound Cc(cc1)cc(CCN23)c1C2=CC(OCc(cc1F)cc(F)c1Oc1cnc(C(F)(F)F)nc1)=NC3=O LQZQSZYECYSUFV-UHFFFAOYSA-N 0.000 description 1
- SDTDOFQFJVINAU-UHFFFAOYSA-N Cc(cc1)ncc1Oc(ccc(CCO)c1)c1F Chemical compound Cc(cc1)ncc1Oc(ccc(CCO)c1)c1F SDTDOFQFJVINAU-UHFFFAOYSA-N 0.000 description 1
- KDUORLUGTVWWLQ-UHFFFAOYSA-N Cc(cc1)ncc1Oc(ccc(COC(C=C1N2CCc3c1ccc(OC)c3)=NC2=O)c1)c1Cl Chemical compound Cc(cc1)ncc1Oc(ccc(COC(C=C1N2CCc3c1ccc(OC)c3)=NC2=O)c1)c1Cl KDUORLUGTVWWLQ-UHFFFAOYSA-N 0.000 description 1
- GQJRPAPJNHJTEF-UHFFFAOYSA-N Cc(nc1)ccc1Oc1ccc(CO)cc1Cl Chemical compound Cc(nc1)ccc1Oc1ccc(CO)cc1Cl GQJRPAPJNHJTEF-UHFFFAOYSA-N 0.000 description 1
- JBGGXIUZIZQNSX-UHFFFAOYSA-N FC(c(cc1)ccc1Oc(cc1)cc(C(F)(F)F)c1Cl)F Chemical compound FC(c(cc1)ccc1Oc(cc1)cc(C(F)(F)F)c1Cl)F JBGGXIUZIZQNSX-UHFFFAOYSA-N 0.000 description 1
- RZFMHGCJZHJULU-UHFFFAOYSA-N N#Cc(cc(C=O)cc1)c1Oc1cnc(C(F)(F)F)nc1 Chemical compound N#Cc(cc(C=O)cc1)c1Oc1cnc(C(F)(F)F)nc1 RZFMHGCJZHJULU-UHFFFAOYSA-N 0.000 description 1
- CVZQCAQFCOMACV-UHFFFAOYSA-N N#Cc(cc(CC=O)cc1)c1Oc1cc(C(F)(F)F)ccc1 Chemical compound N#Cc(cc(CC=O)cc1)c1Oc1cc(C(F)(F)F)ccc1 CVZQCAQFCOMACV-UHFFFAOYSA-N 0.000 description 1
- OHVISZDAPADSBP-UHFFFAOYSA-N N#Cc(cc(CCOC(C=C1N2CCc3c1ccc(F)c3)=NC2=O)cc1)c1Oc(cc1C(F)(F)F)ccc1Cl Chemical compound N#Cc(cc(CCOC(C=C1N2CCc3c1ccc(F)c3)=NC2=O)cc1)c1Oc(cc1C(F)(F)F)ccc1Cl OHVISZDAPADSBP-UHFFFAOYSA-N 0.000 description 1
- LBWZIPYSLCRXBA-UHFFFAOYSA-N N#Cc(cc(CO)cc1)c1Oc(cc1)ncc1Cl Chemical compound N#Cc(cc(CO)cc1)c1Oc(cc1)ncc1Cl LBWZIPYSLCRXBA-UHFFFAOYSA-N 0.000 description 1
- PRPQSMNTWVMION-UHFFFAOYSA-N N#Cc(cc(COC(C=C1N2CCc3c1ccc(F)c3)=NC2=O)cc1)c1Oc1cc(C(F)(F)F)ccc1 Chemical compound N#Cc(cc(COC(C=C1N2CCc3c1ccc(F)c3)=NC2=O)cc1)c1Oc1cc(C(F)(F)F)ccc1 PRPQSMNTWVMION-UHFFFAOYSA-N 0.000 description 1
- OSDJAOKVLDUAAV-UHFFFAOYSA-N N#Cc(cc(COC(C=C1N2CCc3c1cccc3)=NC2=O)cc1)c1Oc1cnc(C(F)(F)F)nc1 Chemical compound N#Cc(cc(COC(C=C1N2CCc3c1cccc3)=NC2=O)cc1)c1Oc1cnc(C(F)(F)F)nc1 OSDJAOKVLDUAAV-UHFFFAOYSA-N 0.000 description 1
- ZPIUXXPRZFOKLX-UHFFFAOYSA-N N#Cc(cc(cc1)Br)c1Oc(cc1C(F)(F)F)ccc1Cl Chemical compound N#Cc(cc(cc1)Br)c1Oc(cc1C(F)(F)F)ccc1Cl ZPIUXXPRZFOKLX-UHFFFAOYSA-N 0.000 description 1
- YXUUCJCERVOZRN-UHFFFAOYSA-N N#Cc(nc1)ccc1Oc(cc1C(F)(F)F)ccc1Cl Chemical compound N#Cc(nc1)ccc1Oc(cc1C(F)(F)F)ccc1Cl YXUUCJCERVOZRN-UHFFFAOYSA-N 0.000 description 1
- ZTOLRUVWXRBHJZ-UHFFFAOYSA-N N#Cc1cc(CCO)ccc1Oc1cccc(C(F)(F)F)c1 Chemical compound N#Cc1cc(CCO)ccc1Oc1cccc(C(F)(F)F)c1 ZTOLRUVWXRBHJZ-UHFFFAOYSA-N 0.000 description 1
- KAXIYYPIORYZLB-UHFFFAOYSA-N N#Cc1cc(O)cnc1 Chemical compound N#Cc1cc(O)cnc1 KAXIYYPIORYZLB-UHFFFAOYSA-N 0.000 description 1
- XDCIOFPXOJUQFV-UHFFFAOYSA-N NCc(cc1)cc(C#N)c1Oc1cc(C(F)(F)F)ccc1 Chemical compound NCc(cc1)cc(C#N)c1Oc1cc(C(F)(F)F)ccc1 XDCIOFPXOJUQFV-UHFFFAOYSA-N 0.000 description 1
- JAELIMBHZGTLOX-UHFFFAOYSA-N NCc(cc1)ccc1Oc1cc(Cl)cnc1 Chemical compound NCc(cc1)ccc1Oc1cc(Cl)cnc1 JAELIMBHZGTLOX-UHFFFAOYSA-N 0.000 description 1
- NUMDIKJSJXNHNQ-UHFFFAOYSA-N O=C(N(CCc1c2ccc(F)c1)C2=C1)N=C1OCc(cc1)cc(F)c1Oc1nc(C(F)(F)F)ccc1 Chemical compound O=C(N(CCc1c2ccc(F)c1)C2=C1)N=C1OCc(cc1)cc(F)c1Oc1nc(C(F)(F)F)ccc1 NUMDIKJSJXNHNQ-UHFFFAOYSA-N 0.000 description 1
- LNOZZAHNOKWRDO-UHFFFAOYSA-N O=C(N(CCc1c2ccc(F)c1)C2=C1)N=C1OCc(cc1F)ccc1Oc1cnc(C(F)(F)F)cc1 Chemical compound O=C(N(CCc1c2ccc(F)c1)C2=C1)N=C1OCc(cc1F)ccc1Oc1cnc(C(F)(F)F)cc1 LNOZZAHNOKWRDO-UHFFFAOYSA-N 0.000 description 1
- HKFTWCYLLSCXHM-UHFFFAOYSA-N O=C(N(CCc1c2cccc1)C2=C1)N=C1Cl Chemical compound O=C(N(CCc1c2cccc1)C2=C1)N=C1Cl HKFTWCYLLSCXHM-UHFFFAOYSA-N 0.000 description 1
- MQEOAYDTJHMWLT-UHFFFAOYSA-N O=C(N(CCc1c2cccc1)C2=C1)N=C1OCc(cc1)cc(F)c1Oc1nc(C(F)(F)F)ccc1 Chemical compound O=C(N(CCc1c2cccc1)C2=C1)N=C1OCc(cc1)cc(F)c1Oc1nc(C(F)(F)F)ccc1 MQEOAYDTJHMWLT-UHFFFAOYSA-N 0.000 description 1
- AKUJAKRCPYMYIL-UHFFFAOYSA-N O=C(N(CCc1cc(F)ccc11)C1=C1)N=C1OCc(cc1)ccc1Oc1cnc(C(F)(F)F)nc1 Chemical compound O=C(N(CCc1cc(F)ccc11)C1=C1)N=C1OCc(cc1)ccc1Oc1cnc(C(F)(F)F)nc1 AKUJAKRCPYMYIL-UHFFFAOYSA-N 0.000 description 1
- FEAIQXYYLIXIGJ-UHFFFAOYSA-N O=Cc(cc1)ccc1Oc1cc(C(F)(F)F)ccc1 Chemical compound O=Cc(cc1)ccc1Oc1cc(C(F)(F)F)ccc1 FEAIQXYYLIXIGJ-UHFFFAOYSA-N 0.000 description 1
- FXGGBYQVSQGHNJ-UHFFFAOYSA-N O=Cc(cc1)ncc1Oc(cc1)cc(C(F)(F)F)c1F Chemical compound O=Cc(cc1)ncc1Oc(cc1)cc(C(F)(F)F)c1F FXGGBYQVSQGHNJ-UHFFFAOYSA-N 0.000 description 1
- LSCMGEBJXSDFPK-UHFFFAOYSA-N O=Cc(cc1F)cc(F)c1Oc1ccc(C(F)(F)F)nc1 Chemical compound O=Cc(cc1F)cc(F)c1Oc1ccc(C(F)(F)F)nc1 LSCMGEBJXSDFPK-UHFFFAOYSA-N 0.000 description 1
- IOESVCKVAYUXEZ-UHFFFAOYSA-N O=Cc(cc1F)ccc1Oc1cncnc1 Chemical compound O=Cc(cc1F)ccc1Oc1cncnc1 IOESVCKVAYUXEZ-UHFFFAOYSA-N 0.000 description 1
- ISFVMFIENWPRHV-UHFFFAOYSA-N O=Cc(nc1)ccc1Oc1cc(C(F)(F)F)ccc1 Chemical compound O=Cc(nc1)ccc1Oc1cc(C(F)(F)F)ccc1 ISFVMFIENWPRHV-UHFFFAOYSA-N 0.000 description 1
- SPDNABJYNDLVPT-UHFFFAOYSA-N OC(c(cc1)ccc1Oc(cc1)cc(C(F)(F)F)c1Cl)=O Chemical compound OC(c(cc1)ccc1Oc(cc1)cc(C(F)(F)F)c1Cl)=O SPDNABJYNDLVPT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2010/077154 | 2010-09-20 | ||
CN2010077154 | 2010-09-20 | ||
PCT/CN2011/001597 WO2012037782A1 (en) | 2010-09-20 | 2011-09-20 | Tricyclic compounds, preparation methods, and their uses |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013537203A true JP2013537203A (ja) | 2013-09-30 |
JP2013537203A5 JP2013537203A5 (US20040106767A1-20040603-C00005.png) | 2014-05-22 |
Family
ID=45873410
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013528497A Pending JP2013537203A (ja) | 2010-09-20 | 2011-09-20 | 三環式化合物、製造方法、およびそれらの使用 |
Country Status (4)
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017520613A (ja) * | 2014-07-22 | 2017-07-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 化合物 |
JP2018502105A (ja) * | 2014-12-26 | 2018-01-25 | 中国科学院上海薬物研究所 | Lp−PLA2阻害剤として用いられるピリミジノン系化合物およびその薬物組成物 |
JP7548606B2 (ja) | 2020-07-10 | 2024-09-10 | 上海紐思克生物科技有限公司 | 三環系ピリミジノン類化合物、その製造方法、その組成物及び使用 |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103649057B (zh) | 2011-07-13 | 2016-05-11 | 巴斯夫农业公司 | 杀真菌的取代的2-[2卤代烷基-4-苯氧基苯基]-1-[1,2,4]三唑-1-基乙醇化合物 |
IN2014CN00832A (US20040106767A1-20040603-C00005.png) | 2011-07-15 | 2015-04-03 | Basf Se | |
BR112014000319B1 (pt) | 2011-07-15 | 2019-05-14 | Basf Se | Usos de compostos da fórmula i, compostos, método de combate a fungos fitopatogênicos, processos de preparação de compostos da fórmula i e composição agroquímica |
UY34259A (es) | 2011-08-15 | 2013-02-28 | Basf Se | Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]-2-alcoxi-3-metil-butil}-1h-[1,2,4]triazol sustituidos |
KR20140054234A (ko) | 2011-08-15 | 2014-05-08 | 바스프 에스이 | 살진균 치환된 1-{2-[2-할로-4-(4-할로겐-페녹시)-페닐]-2-알콕시-2-알키닐/알케닐-에틸}-1h-[1,2,4]트리아졸 화합물 |
JP2014529594A (ja) | 2011-08-15 | 2014-11-13 | ビーエーエスエフ ソシエタス・ヨーロピアBasf Se | 殺菌性置換1−{2−シクリルオキシ−2−[2−ハロ−4−(4−ハロゲン−フェノキシ)−フェニル]−エチル}−1h−[1,2,4]トリアゾール化合物 |
SG2014011886A (en) | 2011-09-01 | 2014-05-29 | Glaxo Group Ltd | Novel crystal form |
CN105050406B (zh) | 2012-12-20 | 2017-09-15 | 巴斯夫农业公司 | 包含三唑化合物的组合物 |
CA2895256C (en) | 2013-01-09 | 2021-06-01 | BASF Agro B.V. | Process for the preparation of substituted oxiranes and triazoles |
JP2016505053A (ja) * | 2013-01-25 | 2016-02-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Lp‐PLA2の阻害剤としての二環式ピリミドン化合物 |
BR112015017759B1 (pt) * | 2013-01-25 | 2022-05-24 | Glaxosmithkline Intellectual Property Development Limited | Compostos inibidores de fosfolipase a2 associada à lipoproteína (lp-pla2) à base de 2,3-dihidroimidazol[1,2-c]pirimidin5(1h)-ona, e composição farmacêutica compreendendo tais compostos |
AR094563A1 (es) | 2013-01-25 | 2015-08-12 | Glaxosmithkline Ip Dev Ltd | Compuesto [5,6]bicíclico de imidazo pirimidona y composición farmacéutica que lo comprende |
EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
ES2860941T3 (es) | 2013-07-08 | 2021-10-05 | Basf Agro Bv | Composiciones que comprenden un compuesto de triazol y un bioplaguicida |
EP3816155A1 (en) * | 2013-08-23 | 2021-05-05 | Virginia Commonwealth University | Ester nitrates derivatives of aromatic aldehydes with multiple pharmalogic properties to treat sickle cell disease |
EP3272217A1 (en) | 2014-06-25 | 2018-01-24 | BASF Agro B.V. | Pesticidal compositions |
WO2016071167A1 (en) | 2014-11-07 | 2016-05-12 | Basf Se | Pesticidal mixtures |
GB201506894D0 (en) | 2015-04-23 | 2015-06-10 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
US10485236B2 (en) | 2015-08-14 | 2019-11-26 | Bayer Cropscience Aktiengesellschaft | Triazole derivatives, intermediates thereof and their use as fungicides |
WO2017093120A1 (en) | 2015-12-01 | 2017-06-08 | Basf Se | Pyridine compounds as fungicides |
US20180368403A1 (en) | 2015-12-01 | 2018-12-27 | Basf Se | Pyridine compounds as fungicides |
US11425909B2 (en) | 2016-03-16 | 2022-08-30 | Basf Se | Use of tetrazolinones for combating resistant phytopathogenic fungi on fruits |
BR112018068705B1 (pt) | 2016-03-16 | 2022-09-06 | Basf Se | Método para controlar fungos fitopatogênicos |
WO2017157910A1 (en) | 2016-03-16 | 2017-09-21 | Basf Se | Use of tetrazolinones for combating resistant phytopathogenic fungi on cereals |
CN107011137B (zh) * | 2017-04-10 | 2020-09-11 | 杭州科耀医药科技有限公司 | 一种匹莫范色林中间体的合成方法 |
US11737463B2 (en) | 2017-05-30 | 2023-08-29 | Basf Se | Pyridine and pyrazine compounds |
CN110818653B (zh) * | 2019-11-08 | 2021-12-28 | 暨南大学 | 苯并噻二嗪类化合物及其应用、ampar的正电子药物 |
CN111533699B (zh) * | 2020-05-27 | 2023-12-01 | 龙曦宁(上海)医药科技有限公司 | 一种2-(三氟甲基)嘧啶-5-醇的合成方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001519798A (ja) * | 1997-04-10 | 2001-10-23 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 抗痙攣作用を有するピリミド−イソキノリン化合物 |
JP2007525475A (ja) * | 2003-07-08 | 2007-09-06 | スミスクライン・ビーチャム・コーポレイション | 新規化学化合物 |
JP2011088847A (ja) * | 2009-10-21 | 2011-05-06 | Takeda Chem Ind Ltd | 三環性化合物およびその用途 |
-
2011
- 2011-09-20 EP EP20110826309 patent/EP2619203A4/en not_active Withdrawn
- 2011-09-20 WO PCT/CN2011/001597 patent/WO2012037782A1/en active Application Filing
- 2011-09-20 JP JP2013528497A patent/JP2013537203A/ja active Pending
- 2011-09-20 US US13/825,034 patent/US8871928B2/en not_active Expired - Fee Related
-
2014
- 2014-09-09 US US14/480,698 patent/US20140378487A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001519798A (ja) * | 1997-04-10 | 2001-10-23 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 抗痙攣作用を有するピリミド−イソキノリン化合物 |
JP2007525475A (ja) * | 2003-07-08 | 2007-09-06 | スミスクライン・ビーチャム・コーポレイション | 新規化学化合物 |
JP2011088847A (ja) * | 2009-10-21 | 2011-05-06 | Takeda Chem Ind Ltd | 三環性化合物およびその用途 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017520613A (ja) * | 2014-07-22 | 2017-07-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 化合物 |
JP2017521456A (ja) * | 2014-07-22 | 2017-08-03 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 化合物 |
JP2018502105A (ja) * | 2014-12-26 | 2018-01-25 | 中国科学院上海薬物研究所 | Lp−PLA2阻害剤として用いられるピリミジノン系化合物およびその薬物組成物 |
JP7548606B2 (ja) | 2020-07-10 | 2024-09-10 | 上海紐思克生物科技有限公司 | 三環系ピリミジノン類化合物、その製造方法、その組成物及び使用 |
Also Published As
Publication number | Publication date |
---|---|
US8871928B2 (en) | 2014-10-28 |
EP2619203A1 (en) | 2013-07-31 |
US20140378487A1 (en) | 2014-12-25 |
WO2012037782A1 (en) | 2012-03-29 |
EP2619203A4 (en) | 2014-04-16 |
US20130178488A1 (en) | 2013-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8871928B2 (en) | Tricyclic compounds, preparation methods, and their uses | |
AU2012289492B2 (en) | 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1H)-one compounds use as Lp-PLA2 inhibitors | |
JP5886310B2 (ja) | Lp−PLA2により媒介される疾患または状態の処置における使用のためのピリミジノン化合物 | |
AU2012288865B2 (en) | Bicyclic pyrimidone compounds | |
JP6306053B2 (ja) | 2,3−ジヒドロイミダゾール[1,2−c]ピリミジン−5(1H)−オンに基づくリポタンパク質関連ホスホリパーゼA2(Lp−PLA2)阻害剤 | |
US8859573B2 (en) | Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130530 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140402 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140402 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150313 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150327 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150901 |